Dapsone clinical trials
Dapsone is named as an intervention in 2 current clinical trials in our Canada, Japan and Egypt registers. 2 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is University of Pennsylvania (1). The most-studied condition is Primary Cutaneous Vasculitis.
Where Dapsone is approved
All regulators →Of the three regulators tracked here, the first to approve Dapsone was the US, on 7 Jul 2005. It is approved in 2 of the 3 regulators tracked here.
- 1 EU orphan designation, most recently for treatment of acute uncomplicated plasmodium falciparum malaria (26 Jul 2002, negative)
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
Dapsone patents and exclusivity
Expiry tracker →Protections still running for marketed products containing Dapsone, as listed by the regulators. Expired patents and exclusivities, and discontinued products, are not shown.
- 1 listed patent; the last listed expires 18 Nov 2033 (US 11273132).
Reproduced from the FDA Orange Book and Purple Book (checked 8 Nov 2026) and the European Commission's Union Register of medicinal products (CC BY 4.0; the EU expiry date is calculated exactly as the Commission's register displays it). Listed patents and dates are as submitted to or published by the regulator and may not reflect litigation, invalidation, settlements, lapsed fees or later extensions. This is not legal advice or a freedom-to-operate opinion, and it does not say when a generic or biosimilar will launch.
What health systems spend on Dapsone
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Dapsone works
All drug targets →- Dihydropteroate synthase 1 inhibitor InhibitorChEMBL only
- COVID-19Phase 3
- Plasmodium falciparum malariaPhase 3
- Plasmodium vivax malariaPhase 3
- Autoimmune thrombocytopenic purpuraPhase 3
- MalariaPhase 3
- Subarachnoid hemorrhagePhase 3
- Ischemic strokePhase 2/3
- Mucous membrane pemphigoidPhase 2/3
- Cutaneous polyarteritis nodosaPhase 2
- ExanthemPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL1043, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 10934, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Dapsone
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Dapsone
- ChEMBL
- CHEMBL1043
- DrugBank
- DB00250
- PubChem CID
- 2955
- CAS number
- 80-08-0
- FDA UNII
- 8W5C518302
- Wikidata
- Q422226
- Wikipedia
- Dapsone
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Dapsone
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Randomized Multicenter Study for Isolated Skin Vasculitis
NCT02939573 · ClinicalTrials.gov ↗ · Primary Cutaneous Vasculitis, Cutaneous Polyarteritis Nodosa, IgA Vasculitis
|
Phase 2 | Recruiting | University of Pennsylvania | Canada, Japan |
|
Rab 32 Gene Polymorphisms as a Prognostic Factor in Leprosy Patients
NCT06819449 · ClinicalTrials.gov ↗ · Leprosy, Mycobacterium Leprae Infection
|
Not applicable | Recruiting | South Valley University | Egypt |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Dapsone
6 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| University of Pennsylvania | 1 |
| South Valley University | 1 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Canada | 1 | 1 |
| Clinical trials in Japan | 1 | 1 |
| Clinical trials in Egypt | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Dapsone trials
How many clinical trials are testing Dapsone?
2 current trials in our Canada, Japan and Egypt registers name Dapsone as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Dapsone trials recruiting patients?
Yes. 2 of the 2 trials are recruiting: 1 with sites in Canada, 1 with sites in Japan and 1 with sites in Egypt. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Dapsone clinical trials?
University of Pennsylvania (1) and South Valley University (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Dapsone works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Dapsone works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Dapsone (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.